Generated by AI
Lisata Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on developing therapies for advanced solid tumors and other major diseases. The company’s lead product candidate, certepetide, is designed to activate a novel uptake pathway that may improve the delivery and penetration of anti-cancer drugs within solid tumors. Lisata Therapeutics’ current work centers on oncology programs that evaluate certepetide in combination with existing cancer regimens across several solid tumor settings. The company also maintains research efforts in other disease areas through its broader development pipeline. Headquartered in Basking Ridge, New Jersey, Lisata Therapeutics plays a role in the biopharmaceutical market by advancing treatment approaches intended to enhance how established therapies reach tumor tissue.
Website110 Allen Road
Basking Ridge, NJ, 07920
United States
The latest articles about LSTA.
SOUTH SAN FRANCISCO, Calif. and LIBERTY CORNER, N.J., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Marea Therapeutics, Inc. (“Marea”), a subsidiary of Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata”), a clinical-stage biotechnology company harnessing the latest advances in human genetics to develop first-in-class, next-generation medicines for cardioendocrine diseases, today announced that management will participate in the following investor conferences: Guggenheim Healthcare Innovation ConferencePrese
Find the latest Lisata Therapeutics, Inc. (LSTA) stock quote, history, news and other vital information to help you with your stock trading and investing.
Summary of Sep 17's posts. Generated by AI.
Summary of Jan 21's posts. Generated by AI.
Summary of Sep 17's posts. Generated by AI.
Investors talking about LSTA also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.